Our mission is to discover drugs for high unmet medical needs that will improve quality of life for patients with Rare Diseases.
We stand out by our ability to deliver high value products with relatively little cost in a short period of time, due to our model we reduce the risk of drug development.
SOM Biotech has a strong pipeline of products focused on CNS at preclinical and clinical stages.
NEWS & PRESS RELEASES
SOM Biotech Announces Initiation of Phase 2a Clinical Trial of SOM3355 in Huntington’s Disease Patients
BARCELONA, Spain and CAMBRIDGE, Massachusetts, July 17, 2018 — SOM Biotech, a clinical-stage biopharmaceutical company that discovers and develops drugs […]
SOM Biotech presents to the BIO.NRW Investors Circle
This year, SOM Biotech was invited to present to the Investors Circle of the Business Angel […]
SOM Biotech receives approval to start Huntington’s disease trial
SOM Biotech has received on 18th June 2018 the approval of the Clinical Trial Application (CTA), the European […]
SOM Biotech at Trifermed Awards 2018
The third edition of Trifermed Awards for Social Impact in Healthcare was held on 14th June […]
1st National Congress on Muscular Dystrophy of Duchenne & Becker 2018
Parent Project España organized the 1st Congreso Nacional Duchenne which was held last 25th-27th May 2018 […]
SOM Biotech at Outsourcing in Clinical Trials Europe 2018
The 8th Annual Outsourcing in Clinical Trials Europe 2018 was held last 15th-16th May 2018 […]
SOM Biotech at Genesis Drug Discovery 2018
The 2nd Annual Genesis Drug Discovery Conference was held last 10th-11th May 2018 in Barcelona, […]
Genesis Drug Discovery: Transforming the Future of Drug Discovery
The 2nd Annual Genesis Drug Discovery: “Transforming the Future of Drug Discovery” brings the most innovative […]
Sant Jordi Festival 2018
Each year, La Diada de Sant Jordi (St. George’s Day) is celebrated on the 23rd […]
Undiagnosed Children’s Day 2018
Undiagnosed Children’s Day is a nationwide event in the UK that occurs on the last Friday […]